# Bioresorbable Sirolimus-eluting scaﬀold in de Novo Coronary Artery Lesions

Study · id `cardio:ct-nct07022587` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07022587](<https://clinicaltrials.gov/study/NCT07022587>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07022587

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 2000 participants.

## Technical summary

Registry record NCT07022587. Randomized; single masking; primary purpose treatment. Start 2025-12-20 (actual); primary completion 2030-12-20 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 2000 participants (planned count; ClinicalTrials.gov record NCT07022587, source copy `cardio:ctgov-nct07022587-2026-02-13`, retrieved 2026-10-26)
- Started: 2025-12-20 (actual) (ClinicalTrials.gov record NCT07022587, source copy `cardio:ctgov-nct07022587-2026-02-13`, retrieved 2026-10-26)
- Primary completion: 2030-12-20 (anticipated) (ClinicalTrials.gov record NCT07022587, source copy `cardio:ctgov-nct07022587-2026-02-13`, retrieved 2026-10-26)
- Completion: 2073-12-20 (anticipated) (ClinicalTrials.gov record NCT07022587, source copy `cardio:ctgov-nct07022587-2026-02-13`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT07022587, source copy `cardio:ctgov-nct07022587-2026-02-13`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07022587-2026-02-13`, retrieved 2026-10-26)

## The registry's words

- Brief title: Bioresorbable Sirolimus-eluting scaﬀold in de Novo Coronary Artery Lesions
- Acronym: REC-CAGEFREE Ⅳ
- Condition: De Novo Stenosis
- Condition: Coronary Artery Disease
- Intervention (Device): Sirolimus-eluting bioresorbable scaffolds
- Intervention (Device): Sirolimus-eluting stents
- Lead sponsor: Xijing Hospital
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry lists this organization as the lead sponsor: Xijing Hospital (`cardio:org-xijing-hospital`)

## Provenance

Content hash: 61bdefdd57a4634931b3285e2a51d2a40677253f4c99b81552bdcb2f415870a9
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
